COVEREX 4 mg tablete Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

coverex 4 mg tablete

egis pharmaceuticals limited - perindopril - tableta - perindopril 3,34 mg / 1 tableta - perindopril

Corlentor Union européenne - slovène - EMA (European Medicines Agency)

corlentor

les laboratoires servier - ivabradinijev klorid - angina pectoris; heart failure - srČno terapija - simptomatsko zdravljenje kronično stabilno angino pektoris pectorisivabradine je primerna za simptomatsko zdravljenje kronična stabilna angina pektoris v koronarna bolezen odraslih z normalno sinus ritem in utrip srca ≥ 70 bpm. ivabradine je navedeno:v odrasli ne morejo prenašati ali z kontraindikacija za uporabo beta-blockersor v kombinaciji z beta blokatorji pri bolnikih neustrezno nadzorovano z optimalno beta-blocker odmerek. zdravljenje kroničnih srce failureivabradine je navedeno v kronično srčno popuščanje nyha ii do iv razred z sistolični motnje, pri bolnikih, pri sinus ritem in katerih srčni utrip ≥ 75 bpm, v kombinaciji s standardno terapijo, vključno z beta-blocker zdravljenja ali pri beta-blocker zdravljenje je kontraindicirano ali ne prenaša.

Lonsurf Union européenne - slovène - EMA (European Medicines Agency)

lonsurf

les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Onivyde pegylated liposomal (previously known as Onivyde) Union européenne - slovène - EMA (European Medicines Agency)

onivyde pegylated liposomal (previously known as onivyde)

les laboratoires servier - irinotecan anhydrous free-base - pankreatične neoplazme - antineoplastična sredstva - zdravljenje metastatskega adenokarcinoma trebušne slinavke, v kombinaciji z 5 flúorouracíl (5-fu) in leucovorin (lv), pri odraslih bolnikih, ki so napredovali po gemcitabin na zdravljenje.

Procoralan Union européenne - slovène - EMA (European Medicines Agency)

procoralan

les laboratoires servier - ivabradinijev klorid - angina pectoris; heart failure - srčna terapija - simptomatsko zdravljenje kronične stabilne angine pektoris ivabradine je indicirano za simptomatsko zdravljenje kronične stabilne angine pektoris pri koronarne bolezni odraslih s običajen sinusni ritem in srčni utrip ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. zdravljenje kroničnega srčnega popuščanja ivabradine navedena v kronično srčno popuščanje nyha ii do iv razreda z sistolični disfunkcija, pri bolnikih v sinusni ritem in katerih srčni utrip je ≥ 75 bpm, v kombinaciji s standardno zdravljenje, vključno z zdravljenjem s beta-blocker ali kdaj je terapija beta-blocker kontraindiciran ali ne prenaša.

Valdoxan Union européenne - slovène - EMA (European Medicines Agency)

valdoxan

les laboratoires servier - agomelatine - depresivna motnja, major

Thymanax Union européenne - slovène - EMA (European Medicines Agency)

thymanax

les laboratoires servier - agomelatine - depresivna motnja, major

Tibsovo Union européenne - slovène - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastična sredstva - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.